FDA asked to drop soy health claims

Feb 19, 2008

A non-profit nutrition education organization has asked the U.S. Food and Drug Administration to drop heart disease health claims for soy protein.

The Weston Price Foundation submitted a petition to the agency Tuesday in response to the FDA's request for public comment on the issue. Manufacturers have been able to market soy as a "heart healthy" food since 1999.

"We have filed this petition because there was never a sound basis for a soy health claim and the heavy marketing of soy as a 'miracle food' has put American men, women and children at risk," said Kaayla Daniel, lead author of the 65-page petition that was officially filed by Sally Fallon, president of the foundation.

The organization, with headquarters in Washington, claims soy protein products aren't safe and have no long history of use in the food supply. The organization also claims the evidence on soy protein and heart disease is "contradictory and inconsistent, and no standard of scientific agreement has been met."

In addition, the foundation notes the American Heart Association in 2006 advised physicians that soy has little effect on cholesterol and is unlikely to prevent heart disease.

Copyright 2008 by United Press International

Explore further: Cardinal Health paying $26.8 million in FTC settlement

Related Stories

Quantum dot TVs are unveiled at China tech expo

29 minutes ago

At this month's China Information Technology Expo (CITE) event, a headline-maker was the launch of quantum dot televisions, by QD Vision and Konka, the consumer electronics company. QD Vision's calling card ...

A call to US educators: Learn from Canada

2 hours ago

As states and the federal government in the U.S. continue to clash on the best ways to improve American education, Canada's Province of Ontario manages successful education reform initiatives that are equal parts cooperation ...

Recommended for you

Cardinal Health paying $26.8 million in FTC settlement

9 hours ago

Cardinal Health will pay $26.8 million as part of a settlement with the Federal Trade Commission over charges it monopolized the sale in 25 markets of diagnostic drugs known as low-energy radiopharmaceuticals.

Selecting the right tool for the job

Apr 14, 2015

Randomized clinical trials of new drugs have long been considered the "gold standard" in determining safety and efficacy before drugs, biologics, vaccines or devices are introduced to the general public. However, in the case ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.